Data gathered: June 5
AI Stock Analysis - Karyopharm Therapeutics (KPTI)
Analysis generated April 23, 2025. Powered by Chat GPT.
Karyopharm Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel, first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. The company's lead product candidate, selinexor, has potential applicability in various oncology indications and represents a significant advancement in the field of cancer therapeutics. Karyopharm's innovative approach in targeting nuclear export pathways distinguishes it from traditional cancer therapies, giving it a competitive edge in the biopharmaceutical market.
Stock Alerts - Karyopharm Therapeutics (KPTI)
 |
Karyopharm Therapeutics | May 30 Price is down by -7.5% in the last 24h. |
|
Karyopharm Therapeutics | May 21 Price is down by -7.9% in the last 24h. |
|
Karyopharm Therapeutics | May 19 Price is down by -7.7% in the last 24h. |
|
Karyopharm Therapeutics | May 15 Price is up by 7% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Karyopharm Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 5 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Employee Rating | 86 | Sign up | Sign up | Sign up |
| Google Trends | 9 | Sign up | Sign up | Sign up |
| Patents | 31 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 12 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,807 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,550 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 78 | Sign up | Sign up | Sign up |
| Linkedin Employees | 360 | Sign up | Sign up | Sign up |
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases.
| Price | $4.26 |
| Target Price | Sign up |
| Volume | 54,800 |
| Market Cap | $37M |
| Year Range | $3.54 - $14.85 |
| Dividend Yield | 0% |
| Analyst Rating | 80% buy |
| Industry | Biotechnology |
In the news
 |
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2 - Yahoo |
 |
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Shares Sold by D. E. Shaw & Co. Inc.May 29 - ETF Daily News |
|
Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock NowMay 25 - Yahoo |
 |
Karyopharm Therapeutics (NASDAQ:KPTI) Cut to Sell at StockNews.comMay 17 - ETF Daily News |
|
Leerink Partnrs Issues Positive Estimate for KPTI EarningsMay 15 - ETF Daily News |
|
Analysts Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) PT at $45.60May 15 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 30M | 1.3M | 29M | -23M | -33M | -2.770 |
| Q4 '24 | 31M | 1.3M | 29M | -31M | -20M | -0.240 |
| Q3 '24 | 39M | 1.3M | 37M | -32M | -21M | -0.257 |
| Q2 '24 | 43M | 1.6M | 41M | 24M | 33M | 0.150 |
| Q1 '24 | 33M | 2M | 31M | -37M | -31M | -0.320 |
Insider Transactions View All
| Paulson Richard A. filed to sell 82,503 shares at $7.1. May 7 '25 |
| Rangwala Reshma filed to sell 28,853 shares at $6.2. April 24 '25 |
| Paulson Richard A. filed to sell 82,739 shares at $3.7. April 7 '25 |
| Abate Kristin filed to sell 9,713 shares at $6.3. March 6 '25 |
| Mano Michael filed to sell 21,047 shares at $6.3. March 6 '25 |
Similar companies
Read more about Karyopharm Therapeutics (KPTI) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Karyopharm Therapeutics?
The Market Cap of Karyopharm Therapeutics is $37M.
What is the current stock price of Karyopharm Therapeutics?
Currently, the price of one share of Karyopharm Therapeutics stock is $4.26.
How can I analyze the KPTI stock price chart for investment decisions?
The KPTI stock price chart above provides a comprehensive visual representation of Karyopharm Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Karyopharm Therapeutics shares. Our platform offers an up-to-date KPTI stock price chart, along with technical data analysis and alternative data insights.
Does KPTI offer dividends to its shareholders?
As of our latest update, Karyopharm Therapeutics (KPTI) does not offer dividends to its shareholders. Investors interested in Karyopharm Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Karyopharm Therapeutics?
Some of the similar stocks of Karyopharm Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.